Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...
– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results